IN2014MN01937A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01937A
IN2014MN01937A IN1937MUN2014A IN2014MN01937A IN 2014MN01937 A IN2014MN01937 A IN 2014MN01937A IN 1937MUN2014 A IN1937MUN2014 A IN 1937MUN2014A IN 2014MN01937 A IN2014MN01937 A IN 2014MN01937A
Authority
IN
India
Prior art keywords
subject
metabolic syndrome
diabetes mellitus
risk
level
Prior art date
Application number
Other languages
English (en)
Inventor
Andreas Bergmann
Olle Melander
Original Assignee
Sphingotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphingotec Gmbh filed Critical Sphingotec Gmbh
Publication of IN2014MN01937A publication Critical patent/IN2014MN01937A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • G01N2333/4706Regulators; Modulating activity stimulating, promoting or activating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1937MUN2014 2012-03-08 2013-03-08 IN2014MN01937A (https=)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261608350P 2012-03-08 2012-03-08
EP12158680 2012-03-08
EP12165062 2012-04-20
PCT/EP2013/054801 WO2013132090A1 (en) 2012-03-08 2013-03-08 A method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject

Publications (1)

Publication Number Publication Date
IN2014MN01937A true IN2014MN01937A (https=) 2015-07-10

Family

ID=49115970

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1937MUN2014 IN2014MN01937A (https=) 2012-03-08 2013-03-08

Country Status (9)

Country Link
US (2) US10520512B2 (https=)
EP (1) EP2823316B1 (https=)
JP (1) JP6262669B2 (https=)
CN (1) CN103308670B (https=)
ES (1) ES2684512T3 (https=)
IN (1) IN2014MN01937A (https=)
RU (1) RU2685713C2 (https=)
TR (1) TR201811201T4 (https=)
WO (1) WO2013132090A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103308689B (zh) * 2012-03-08 2017-04-12 思芬构技术有限公司 用于预测雌性对象中患上癌症的风险或诊断癌症的方法
EP3002589A1 (en) * 2014-10-01 2016-04-06 sphingotec GmbH A method for stratifying a female subject for hormone replacement therapy
ES2781084T3 (es) * 2015-02-27 2020-08-28 Sphingotec Gmbh Un método para predecir el riesgo de obesidad en un sujeto
US10473670B2 (en) 2016-02-25 2019-11-12 University Of Kentucky Research Foundation Method of predicting obesity comprising measuring neurotensin
WO2022203533A1 (ru) * 2021-03-25 2022-09-29 Владимир Валерьевич ВОЛОБУЕВ Способ оценки предрасположенности к различным формам сахарного диабета 2го типа

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5430047A (en) * 1994-04-07 1995-07-04 Warner-Lambert Company Neurotensin antagonists
WO1995033474A1 (en) * 1994-06-03 1995-12-14 Tsumura & Co. Medicinal composition
JP4394279B2 (ja) * 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
US6248527B1 (en) * 1998-10-21 2001-06-19 Millennium Pharmaceuticals, Inc. Method of detecting risk of type II diabetes based on mutations found in carboxypeptidase E
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
US7271153B2 (en) * 2001-06-20 2007-09-18 Kissei Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor
RU2004109222A (ru) 2001-08-30 2005-10-20 Байорексис Фармасьютикал Корпорейшн (Us) Слитые белки модифицированного трансферрина
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
DE102005003687A1 (de) * 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
WO2006110082A1 (en) * 2005-04-11 2006-10-19 Astrazeneca Ab A method and a kit for diagnosing type 2 diabetes, metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes.
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
EP3785735A1 (en) 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
CA2745524C (en) * 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2374003B1 (en) 2009-01-07 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment, the prognostic assessment and the detection of breast cancer
MX2012002428A (es) 2009-08-27 2012-09-12 Covagen Ag Compuestos de union il-17 y usos medicos de los mismos.
US9217747B2 (en) * 2009-10-29 2015-12-22 Health Diagnostic Laboratory, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
AU2010332932B2 (en) 2009-12-14 2013-01-17 Navigo Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin
UA58612U (uk) * 2010-06-04 2011-04-26 Высшее Государственное Учебное Заведение «Украинская Медицинская Стоматологическая Академия» Спосіб діагностики інсулінорезистентності у хворих на метаболічний синдром та цукровий діабет 2 типу
RU2569745C2 (ru) 2010-06-08 2015-11-27 Пиерис АГ Мутеины липокалина слезы, связывающие альфа il-4 r
ES2781084T3 (es) * 2015-02-27 2020-08-28 Sphingotec Gmbh Un método para predecir el riesgo de obesidad en un sujeto

Also Published As

Publication number Publication date
US20150056203A1 (en) 2015-02-26
ES2684512T3 (es) 2018-10-03
JP2015512048A (ja) 2015-04-23
EP2823316B1 (en) 2018-05-23
CN103308670A (zh) 2013-09-18
US10520512B2 (en) 2019-12-31
EP2823316A1 (en) 2015-01-14
RU2685713C2 (ru) 2019-04-23
JP6262669B2 (ja) 2018-01-17
US20200326350A1 (en) 2020-10-15
TR201811201T4 (tr) 2018-09-21
RU2014140427A (ru) 2016-04-27
CN103308670B (zh) 2017-06-09
WO2013132090A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
WO2013159872A8 (en) Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope
HK1223795A1 (zh) 拉喹莫德响应性的基因表达生物标志物
IN2014MN01937A (https=)
NZ630421A (en) Biomarkers predictive for clinical response for glatiramer acetate
WO2013084002A3 (en) Method for detecting nucleosome adducts
EA201590027A1 (ru) Способы детекции заболеваний или состояний
NZ601590A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112013000760A2 (pt) método e aparelho para medir a espessura do tecido adiposo
BR112015003046A2 (pt) sistema de neurofeedback, processador de sinal para determinação de uma característica do sinal do sinal do biofeedback medido, método para provisão de um usuário com o neurofeedback e programa de computador.
WO2012012693A3 (en) Methods for detecting signatures of disease or conditions in bodily fluids
WO2010148391A3 (en) Biomarker assay of neurological condition
WO2013067495A3 (en) Personal spirometer
WO2014004889A3 (en) Plasma analytes predict diagnosis and prognosis of thoracic aortic aneurysm
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
MX2015012304A (es) Metodo no invasivo para la medicion de metabolitos para la salud de la piel.
WO2014053466A3 (en) System and method for assessing risk associated with a glucose state
WO2012078623A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
MX2017003370A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
MX359328B (es) Metodo para el diagnostico de enfermedad de niemann-pick.
IN2014MN01940A (https=)
BR112015014232A2 (pt) lesão renal aguda
RU2010145662A (ru) Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
WO2015010042A3 (en) Method of determination of risk of 2 hour blood glucose equal to or greater than 140 mg/di
WO2013132089A3 (en) A method for predicting the risk of getting cancer or diagnosing cancer in a female subject
WO2016066862A3 (en) A method for predicting the risk of obesity in a subject